SG10201914117QA - Treatment Of Myelosuppression - Google Patents

Treatment Of Myelosuppression

Info

Publication number
SG10201914117QA
SG10201914117QA SG10201914117QA SG10201914117QA SG10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA
Authority
SG
Singapore
Prior art keywords
treatment
myelosuppression
treatment regimens
thrombopoies
administering
Prior art date
Application number
SG10201914117QA
Inventor
Stephen Marcus
Original Assignee
Cantex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantex Pharmaceuticals Inc filed Critical Cantex Pharmaceuticals Inc
Publication of SG10201914117QA publication Critical patent/SG10201914117QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Treatment Of Myelosuppression Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoies is and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids. [Figure 13A]
SG10201914117QA 2012-05-09 2013-03-13 Treatment Of Myelosuppression SG10201914117QA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261644623P 2012-05-09 2012-05-09
US201261644556P 2012-05-09 2012-05-09
US201261648043P 2012-05-16 2012-05-16
US201261653362P 2012-05-30 2012-05-30
US201261664611P 2012-06-26 2012-06-26
US201261668709P 2012-07-06 2012-07-06
US201261678053P 2012-07-31 2012-07-31
US201261702207P 2012-09-17 2012-09-17
US201261724836P 2012-11-09 2012-11-09

Publications (1)

Publication Number Publication Date
SG10201914117QA true SG10201914117QA (en) 2020-02-27

Family

ID=49549076

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201914117QA SG10201914117QA (en) 2012-05-09 2013-03-13 Treatment Of Myelosuppression
SG11201407340YA SG11201407340YA (en) 2012-05-09 2013-03-13 Treatment of myelosuppression
SG10201603059YA SG10201603059YA (en) 2012-05-09 2013-03-13 Treatment Of Myelosuppression

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201407340YA SG11201407340YA (en) 2012-05-09 2013-03-13 Treatment of myelosuppression
SG10201603059YA SG10201603059YA (en) 2012-05-09 2013-03-13 Treatment Of Myelosuppression

Country Status (21)

Country Link
US (6) US9271999B2 (en)
EP (2) EP2846809B1 (en)
JP (3) JP6177885B2 (en)
KR (2) KR102452803B1 (en)
CN (3) CN104411316B (en)
AU (1) AU2013260101B2 (en)
BR (1) BR112014028094B1 (en)
CA (2) CA3122808A1 (en)
CL (2) CL2014003017A1 (en)
DK (1) DK2846809T3 (en)
EA (1) EA029382B1 (en)
ES (1) ES2848050T3 (en)
HK (1) HK1207574A1 (en)
HU (1) HUE053247T2 (en)
IL (1) IL235593B (en)
LT (1) LT2846809T (en)
MX (2) MX370567B (en)
PL (1) PL2846809T3 (en)
PT (1) PT2846809T (en)
SG (3) SG10201914117QA (en)
WO (1) WO2013169355A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102452803B1 (en) 2012-05-09 2022-10-07 캔텍스 파마슈티칼즈, 인크. Treatment of myelosuppression
SG11201603081WA (en) * 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
WO2016133910A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
BR112017018954A2 (en) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. Use of Ras Protein Mutant Form and Method to Treat Cancer
CN113735834B (en) 2015-07-13 2023-06-13 大连万春布林医药有限公司 Plinabulin composition
IL260933B2 (en) 2016-02-08 2023-04-01 Beyondspring Pharmaceuticals Inc Plinabulin compositions
KR20190015361A (en) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. Compositions and methods for reducing neutropenia
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
SG11201907023UA (en) 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
CN107569486A (en) * 2017-08-23 2018-01-12 北京京佑奇康生物科技有限公司 Menglusitena treats the new application of thrombopenia
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20200112881A (en) * 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. Composition and method for reducing thrombocytopenia through administration of plinabulin
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
KR20210119469A (en) * 2019-01-25 2021-10-05 잔센파마슈티카엔.브이. Methods to promote protection, hematopoietic recovery and survival against organ and vascular damage in response to systemic radiation/chemical exposure
JP2022529781A (en) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド Treatment of depression and various other disorders with psilocybin
WO2021041532A1 (en) * 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
TW202128616A (en) * 2019-11-13 2021-08-01 日商大鵬藥品工業股份有限公司 Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
WO2021207697A1 (en) 2020-04-10 2021-10-14 Cantex Pharmaceuticals, Inc. Treatment of acute lung injury
EP4182452A1 (en) 2020-07-14 2023-05-24 Optimvia, LLC Methods for synthesizing non-anticoagulant heparan sulfate
KR20230058289A (en) 2021-10-21 2023-05-03 숙명여자대학교산학협력단 Combination therapy with griseofulvin for blood cancer

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (en) 1976-10-23 1978-07-21 Choay Sa PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
FR2553287B1 (en) 1983-10-18 1986-09-12 Choay Sa COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES OR OLIGOSACCHARIDES, ESPECIALLY BASED ON HEPARIN FRACTIONS OR FRAGMENTS, SUITABLE FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS
DE3422518A1 (en) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen HEPARIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF FATTY METABOLISM DISORDERS
FR2584606A1 (en) 1985-07-12 1987-01-16 Dropic USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
IT1234826B (en) 1989-01-30 1992-05-29 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
WO1991015216A1 (en) 1990-04-05 1991-10-17 Kennedy Thomas P Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
IT1254216B (en) 1992-02-25 1995-09-14 Opocrin Spa POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5306724A (en) 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
GB2270841A (en) 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
AU6246394A (en) 1993-02-22 1994-09-14 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
SE9302135D0 (en) 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
CA2189038A1 (en) 1994-05-06 1995-11-09 Kevin R. Holme O-desulfated heparin derivatives, methods of making and uses thereof
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
AU727352B2 (en) 1996-07-29 2000-12-14 Paringenix, Inc. Methods of treating asthma with o-desulfated heparin
US6154502A (en) 1996-08-22 2000-11-28 Intel Corporation Signal constellation slicer
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
AU741802B2 (en) 1997-02-15 2001-12-13 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of NF-kappaB
WO1998053852A1 (en) 1997-05-30 1998-12-03 Arch Development Corporation P-selectin translocation to vascular epithelial lumen by ionizing radiation
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6514502B1 (en) 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
AU763042B2 (en) 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
DE60223670T2 (en) * 2001-04-18 2008-03-06 Prometic Biosciences Inc., Mont-Royal Fatty acids as factors for survival and activation of neutrophils.
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
EP1523310A2 (en) 2002-07-09 2005-04-20 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
AU2003293122A1 (en) 2002-11-27 2004-06-23 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
AU2004251599A1 (en) 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7538096B2 (en) 2004-03-16 2009-05-26 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
PT1744764E (en) * 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Liposomal formulations of anthracycline agents and cytidine analogs
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US7468358B2 (en) 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP2006076968A (en) 2004-09-10 2006-03-23 Seikagaku Kogyo Co Ltd Physiologically active molecule-containing crosslinked heparin gel composition
JP2009507209A (en) 2005-07-22 2009-02-19 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア Heparin composition and selectin inhibition
WO2007019554A2 (en) 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
AU2006298188B2 (en) 2005-09-30 2012-03-15 Takara Bio Inc. Method for production of T cell population
ZA200806192B (en) 2005-12-16 2009-12-30 Dpn Canada Inc Chitin derivatives for hyperlipidemia
WO2007115372A1 (en) 2006-04-10 2007-10-18 Monash University A method of modulating beta-amyloid peptide production
PL2043662T3 (en) 2006-07-26 2016-03-31 Intrexon Corp Methods and compositions for treating disease
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
US20090054374A1 (en) 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
CA2689914C (en) * 2007-06-01 2016-08-16 Abraxis Bioscience, Llc Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers
JP2010534672A (en) 2007-07-23 2010-11-11 ユニバーシティ オブ ユタ リサーチ ファウンデーション Method for blocking glycation end product receptor (RAGE) ligation
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20090238852A1 (en) 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
MX2010010904A (en) 2008-04-04 2010-11-04 Univ Utah Res Found Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof.
US8476249B2 (en) * 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US20130034534A1 (en) 2009-09-29 2013-02-07 Philipp Kroneberg Method for treatment of patients with cystic fibrosis
CN102917711A (en) 2010-03-12 2013-02-06 澳大利亚国立大学 Heparan sulfate replacement therapy
AU2011231978B2 (en) * 2010-03-24 2014-12-18 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
EP3153173A1 (en) 2010-06-28 2017-04-12 Stemtech International, Inc. Methods and compositions for enhancing stem cell mobilization
WO2012106299A1 (en) * 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012106379A1 (en) 2011-02-01 2012-08-09 Paringenix, Inc. Sensitization of cancer cells to treatment
WO2013016181A1 (en) 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
MX2014013049A (en) 2012-05-01 2015-03-19 Univ Duke Compositions and methods for heparan sulfate as a biomarker for transplant rejection.
KR102452803B1 (en) 2012-05-09 2022-10-07 캔텍스 파마슈티칼즈, 인크. Treatment of myelosuppression
KR102503695B1 (en) 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods and compositions for mobilizing stem cells
SG11201603081WA (en) 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
WO2015061604A1 (en) 2013-10-24 2015-04-30 Thomas Kennedy Treating bacterial infections of the lung
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
EP3258940A1 (en) 2015-02-17 2017-12-27 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US20170106011A1 (en) 2015-10-20 2017-04-20 Cantex Pharmaceuticals, Inc. Methods of treating traumatic brain injury and sequelae
WO2017123549A1 (en) 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids

Also Published As

Publication number Publication date
CN108498532A (en) 2018-09-07
MX2014013633A (en) 2015-07-06
US20200038431A1 (en) 2020-02-06
KR102452803B1 (en) 2022-10-07
KR20150023361A (en) 2015-03-05
HUE053247T2 (en) 2021-06-28
LT2846809T (en) 2021-01-25
BR112014028094B1 (en) 2022-03-03
EP2846809A4 (en) 2015-12-30
IL235593A0 (en) 2015-01-29
CL2021000008A1 (en) 2021-06-11
US8734804B2 (en) 2014-05-27
CA2872855C (en) 2021-07-27
EP2846809B1 (en) 2020-10-14
SG11201407340YA (en) 2014-12-30
US20220354882A1 (en) 2022-11-10
CA3122808A1 (en) 2013-11-14
KR20200118510A (en) 2020-10-15
SG10201603059YA (en) 2016-05-30
AU2013260101B2 (en) 2016-10-27
PL2846809T3 (en) 2021-07-26
PT2846809T (en) 2021-02-05
ES2848050T3 (en) 2021-08-05
US11229664B2 (en) 2022-01-25
AU2013260101A1 (en) 2014-12-18
EA029382B1 (en) 2018-03-30
WO2013169355A1 (en) 2013-11-14
HK1207574A1 (en) 2016-02-05
CA2872855A1 (en) 2013-11-14
EP2846809A1 (en) 2015-03-18
IL235593B (en) 2019-06-30
EA201492052A1 (en) 2015-08-31
KR102165348B1 (en) 2020-10-14
US9271999B2 (en) 2016-03-01
EP3785720A1 (en) 2021-03-03
JP6448694B2 (en) 2019-01-09
MX370567B (en) 2019-12-17
CL2014003017A1 (en) 2015-07-10
CN104411316A (en) 2015-03-11
CN108498532B (en) 2021-07-23
JP2017105850A (en) 2017-06-15
US20130323230A1 (en) 2013-12-05
BR112014028094A2 (en) 2020-06-30
JP2019026647A (en) 2019-02-21
MX2019009437A (en) 2019-10-02
JP6177885B2 (en) 2017-08-09
US20160213706A1 (en) 2016-07-28
CN104411316B (en) 2018-05-01
CN113521093A (en) 2021-10-22
US20130303481A1 (en) 2013-11-14
JP2015521176A (en) 2015-07-27
US20180296590A1 (en) 2018-10-18
JP6726252B2 (en) 2020-07-22
DK2846809T3 (en) 2021-01-18

Similar Documents

Publication Publication Date Title
SG10201914117QA (en) Treatment Of Myelosuppression
IN2014DN09434A (en)
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX363243B (en) Compositions and methods for treating cancer.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2015002669A (en) Methods of administering pirfenidone therapy.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MY181828A (en) Bicyclically substituted uracils and the use therapy
MX2014013752A (en) Nampt inhibitors.
MX353299B (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer.
MX2015003701A (en) Treatment compositions.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
PH12014500990A1 (en) Methods for treating gout flares
MX340536B (en) Egfr targeted therapy.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
MX2013011694A (en) Taxane and abeo-taxane analogs.
GB2515440A (en) Vesicular formulations
IN2014DN03010A (en)
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
AU2012240388A8 (en) Treatment regimens
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
MX2015001695A (en) Treatment regimens.
PL2644202T3 (en) Ointment for skin treatment, and method of its manufacture
MY177715A (en) Use of pidotimod to treat atopic dermatitis
UA80419U (en) Method for treating metaepiphyseal osteomyelitis in children